Baxter International Inc Total Liabilities
Baxter International Inc total liabilities. Based on the latest financial reports, Baxter International Inc (BAX) has total liabilities worth $13.61 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BAX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Baxter International Inc (1985–2025)
Total liabilities of Baxter International Inc from 1985 to 2025. This chart illustrates how Baxter International Inc's total liabilities have evolved over time, based on quarterly financial data. Check BAX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Baxter International Inc Competitors by Total Liabilities
The table below lists competitors of Baxter International Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TKO Group Holdings, Inc.
NYSE:TKO
|
USA | $7.50 Billion |
|
LATAM Airlines Group S.A.
NYSE:LTM
|
USA | $16.78 Billion |
|
Shanghai Rural Commercial Bank Co Ltd
SHG:601825
|
China | CN¥1.51 Trillion |
|
Eurobank Ergasias Services and Holdings S.A.
AT:EUROB
|
Greece | €93.20 Billion |
|
POWSZECHNY Z.U.ADR /1 ZY1
F:7PZ0
|
Germany | €468.73 Billion |
|
Kingspan Group plc
IR:KRX
|
Ireland | €5.22 Billion |
|
Taiwan Mobile Co Ltd
TW:3045
|
Taiwan | NT$145.33 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Baxter International Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BAX total asset value.
Liquidity & Leverage Metrics
Baxter International Inc Total Liabilities Ratios Explained
Baxter International Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Baxter International Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Baxter International Inc (1985–2025)
The table below shows the annual total liabilities of Baxter International Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $13.95 Billion | -25.62% |
| 2024-12-31 | $18.76 Billion | -5.30% |
| 2023-12-31 | $19.81 Billion | -11.54% |
| 2022-12-31 | $22.39 Billion | -8.23% |
| 2021-12-31 | $24.40 Billion | +116.06% |
| 2020-12-31 | $11.29 Billion | +9.84% |
| 2019-12-31 | $10.28 Billion | +30.90% |
| 2018-12-31 | $7.85 Billion | -1.76% |
| 2017-12-31 | $8.00 Billion | +10.03% |
| 2016-12-31 | $7.27 Billion | -39.94% |
| 2015-12-31 | $12.10 Billion | -32.73% |
| 2014-12-31 | $17.98 Billion | +7.43% |
| 2013-12-31 | $16.74 Billion | +24.80% |
| 2012-12-31 | $13.41 Billion | +9.53% |
| 2011-12-31 | $12.24 Billion | +14.51% |
| 2010-12-31 | $10.69 Billion | +7.64% |
| 2009-12-31 | $9.93 Billion | +8.26% |
| 2008-12-31 | $9.18 Billion | +9.52% |
| 2007-12-31 | $8.38 Billion | -0.43% |
| 2006-12-31 | $8.41 Billion | -0.17% |
| 2005-12-31 | $8.43 Billion | -19.29% |
| 2004-12-31 | $10.44 Billion | +0.09% |
| 2003-12-31 | $10.43 Billion | +9.37% |
| 2002-12-31 | $9.54 Billion | +44.84% |
| 2001-12-31 | $6.59 Billion | +8.43% |
| 2000-12-31 | $6.07 Billion | -3.53% |
| 1999-12-31 | $6.30 Billion | -10.49% |
| 1998-12-31 | $7.03 Billion | +15.54% |
| 1997-12-31 | $6.09 Billion | +19.56% |
| 1996-12-31 | $5.09 Billion | -11.18% |
| 1995-12-31 | $5.73 Billion | -8.74% |
| 1994-12-31 | $6.28 Billion | -14.65% |
| 1993-12-31 | $7.36 Billion | +37.31% |
| 1992-12-31 | $5.36 Billion | +7.91% |
| 1991-12-31 | $4.97 Billion | +12.25% |
| 1990-12-31 | $4.42 Billion | +3.95% |
| 1989-12-31 | $4.26 Billion | -21.95% |
| 1988-12-31 | $5.45 Billion | +13.51% |
| 1987-12-31 | $4.80 Billion | +4.96% |
| 1986-12-31 | $4.58 Billion | -3.76% |
| 1985-12-31 | $4.76 Billion | -- |
About Baxter International Inc
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable p… Read more